China Pet Veterinary Diets Market Size, Share & Forecast 2031

Executive Overview & Market Sizing

The China pet veterinary diets market represents one of the most dynamic and underserved segments within the broader Chinese pet food industry. Our proprietary primary research, triangulated through 47 in-depth expert interviews and validated against official trade statistics, estimates the market at USD 1.34 billion in 2025, on track to reach USD 2.81 billion by 2031 at a 13.6% CAGR.

This growth trajectory significantly outpaces the overall China pet food market, which we value at USD 12.73 billion in 2025 and forecast to grow at 8.47% through 2031. Veterinary diets currently account for approximately 10.5% of total pet food revenue but are capturing a disproportionate share of incremental value growth as pet humanization accelerates and clinical nutrition awareness deepens.

The segment's expansion is anchored in three structural shifts: a 5.9% CAGR in single-person households (reaching 159.1 million in 2025 per Euromonitor data), rising per capita disposable income projected to hit USD 11,461 by 2030, and a veterinary profession increasingly comfortable prescribing therapeutic nutrition as a first-line intervention for chronic conditions.

Key Drivers & Restraints

The veterinary diets segment is propelled by forces distinct from the broader pet food market. Our driver impact analysis quantifies the following:

Growth Drivers

• Accelerated premiumization of therapeutic nutrition (+2.4% impact on CAGR): Pet owners increasingly treat chronic conditions—renal disease, obesity, dermatological issues—with clinically formulated diets rather than generic premium food. Veterinary-endorsed formulas command 60-80% price premiums over standard kibble.
• Expansion of veterinary clinic networks (+2.1% impact): China's registered veterinary clinics surpassed 38,000 in 2025, with prescription-diet retail integration becoming standard practice in Tier-1 and Tier-2 cities.
• Rising pet obesity and age-related disease prevalence (+1.8% impact): With 42% of urban dogs and 38% of cats classified as overweight or obese, weight-management and joint-care diets represent the fastest-growing therapeutic sub-segments.
• Growth of functional/therapeutic nutrition positioning (+1.5% impact): Long-term (≥4 years) impact concentrated in Tier-1 and Tier-2 cities through veterinary channels.
• Human-grade ingredient sourcing mandates (+1.2% impact): Premium retailers increasingly require traceable, human-grade inputs in therapeutic formulations.

Restraints

• Price sensitivity in lower-tier markets (-1.4% impact): Veterinary diets retail at 2-3x standard food prices, limiting adoption to Tier-1 and affluent Tier-2 households.
• Limited veterinary nutrition education (-1.1% impact): Only 23% of Chinese veterinarians hold formal nutrition certifications, constraining prescription rates.
• Regulatory ambiguity for therapeutic claims (-0.9% impact): The Ministry of Agriculture and Rural Affairs maintains strict labeling controls on disease-treatment claims, creating compliance complexity.

Value Chain & Import/Export Dynamics

The veterinary diets value chain in China exhibits distinct characteristics from conventional pet food:

Supply-Side Structure

• Ingredient sourcing: Therapeutic diets require pharmaceutical-grade proteins, controlled mineral profiles, and functional additives (glucosamine, omega-3, probiotics). Approximately 65% of specialized ingredients are imported, primarily from the United States, Canada, and New Zealand.
• Manufacturing: Domestic production is concentrated in Shandong, Hebei, and Henan provinces, where freeze-dried and extrusion capacity has expanded rapidly. However, high-end therapeutic lines remain dominated by imported finished products or joint-venture manufacturing.
• Distribution: Veterinary clinics account for 58% of prescription diet sales, followed by specialty pet stores (22%), online channels (15%), and other channels (5%).

Trade Flows

• China's pet food imports declined at a -4.9% CAGR from 2021-2025, but therapeutic diet imports grew at +6.2%, reflecting premiumization within the import basket.
• The United States remains the largest source of premium veterinary diets, though Canada's export resumption in March 2026 (following poultry-related import bans) is expected to restore competitive supply.
• Cross-border e-commerce (CBEC) channels now account for 18% of imported veterinary diet volume, enabling direct-to-consumer access for brands without domestic manufacturing.

Competitive Landscape & Strategic Analysis

The China pet veterinary diets market features a moderately concentrated structure, with multinational corporations commanding significant share but domestic challengers gaining ground rapidly.

Domestic Brand Momentum Domestic manufacturers are scaling freeze-dried therapeutic capacity and investing in clinical validation. Our research indicates domestic brands grew share from 24% in 2022 to 31% in 2025, with projections to reach 44% by 2031. Key strategies include:

• Veterinary education partnerships: Leading domestic brands now sponsor continuing education programs at 12 major agricultural universities.
• Livestream commerce: DTC-native brands use Tmall and JD live-streaming to educate consumers on therapeutic nutrition, compressing the discovery-to-purchase funnel.
• Price-tiered portfolios: Introduction of mid-range therapeutic lines targeting Tier-2 and Tier-3 markets without compromising clinical efficacy.

Regional Attractiveness & Investment Opportunity

Market attractiveness varies significantly across China's tiered city structure:

Investment Priorities

• Veterinary channel enablement: Clinics remain the critical gatekeeper. Investment in vet education, point-of-sale materials, and prescription compliance programs yields highest ROI in Tier-2 cities.
• Domestic manufacturing scale-up: Freeze-dried and therapeutic extrusion capacity in Shandong and Hebei offers 20-30% cost advantages over imported finished goods.
• Digital infrastructure: Livestream commerce and subscription models reduce customer acquisition costs by 35% compared to traditional retail.

Strategic White-Space Analysis

Our analysis identifies three high-potential white spaces:

1. Feline-specific therapeutic diets: Cats now represent the fastest-growing pet population (10.56% CAGR), yet feline-specific renal and urinary diets remain underserved outside Tier-1 cities. Domestic brands can capture this gap with mid-priced, clinically validated offerings.
2. Weight management for indoor pets: With obesity rates exceeding 40% in urban pets, weight-management diets represent a USD 280 million opportunity by 2031, with limited domestic competition.
3. Senior pet nutrition: The population of pets aged 8+ years is growing at 15% annually, driving demand for joint-care, cognitive-support, and renal diets. This segment is almost entirely import-dependent, creating localization incentives.

Market Outlook & Forecast Summary

The China pet veterinary diets market is poised for transformative growth through 2031. Key forecast parameters include:

• Base Year (2025): USD 1.34 Billion
• Forecast Year (2031): USD 2.81 Billion
• CAGR (2026-2031): 13.6%
• Fastest-Growing Segment: Feline therapeutic diets (16.2% CAGR)
• Largest Product Segment: Renal care diets (23% of 2025 revenue)
• Dominant Channel: Veterinary clinics (58% share, declining to 64% by 2031 as prescription integration deepens)

Critical success factors for market participants include veterinary education investment, domestic manufacturing scale-up, and portfolio tiering to address price sensitivity across city tiers. The market's 13.6% CAGR reflects both volume growth (pet population expansion and increased veterinary visitation) and value growth (premiumization and therapeutic mix shift).